AlphAIalphai — Financial news for AI agents
thehindubusinessline.comMAY 296 min read$ESAB

Q4 Results 29th May Live: Asian Paints, IndiGo, NMDC, Glenmark Pharma, Ipca Lab, IREDA, Gujarat Gas, Natco Pharma, Inox Wind, Rubicon Research, BEML, NMDC Steel, JM Financial, Triveni Engg to announce

The article previews Q4 results from multiple Indian companies and highlights several earnings updates. Prime Focus reported standalone net profit of Rs 4.32 crore for March 2026 quarter vs Rs 16.11 crore loss a year earlier. Alkem Laboratories’ standalone net profit fell to Rs 217 crore from Rs 276.9 crore; it recommended a final dividend of Rs 10/share. It also cites Q4FY26 figures for ESAB India, Ecos Mobility, and Ivalue Infosolutions, plus early stock moves.

Original reporting
thehindubusinessline.com
Published May 29, 2026, 4:45 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 29, 2026, 5:07 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Q4 Results 29th May Live: Asian Paints, IndiGo, NMDC, Glenmark Pharma, Ipca Lab, IREDA, Gujarat Gas, Natco Pharma, Inox Wind, Rubicon Research, BEML, NMDC Steel, JM Financial, Triveni Engg to announce — source image
Source · thehindubusinessline.com
Decision brief

The 30-second read

$ESABNeutralMed
01

Why it matters

Because it mixes an earnings calendar with some company-specific profit/margin figures, tradability is highest for the names where the article provides concrete earnings/dividend numbers or a stated stock move.

02

Market read

Traders should treat this as an earnings-volatility watchlist with actionable edge only where the article includes actual earnings/dividend datapoints or a stated price reaction.

03

What to watch

For several names, the article provides only lineup/first-cut context; actual order book, guidance, and cash-flow details at release are the real drivers.

Relevance 7/10Novelty 4/10Timing: pre-market / ahead of Q4 earnings prints listed for 29 May

Background

The piece is a live/preview-style roundup of multiple Indian companies scheduled to announce Q4 results on 29 May, plus embedded analyst first-cut notes and a few standalone profit/dividend datapoints.

Company-level read

Ticker impact

$ESABNeutralMedium confidence
Context

ESAB India (ESAB India Ltd.) is analyzed with Q4FY26 consolidated revenue/EBITDA/PAT and margin drivers, informing trading expectations.

Expected impact

Likely choppy trade: margin disappointment vs partial offset from land-sale gain and price hikes.

Evidence & confidence

The article provides detailed Q4 and FY26 datapoints for ESAB India, though it’s framed as analyst notes.

Market effects

Sector

Broad Q4 earnings calendar across paints, airlines, pharma, steel, and industrials can shift sector-level risk appetite and read-across expectations.

Regional

India-focused earnings flow can drive intraday index volatility and rotation within NSE/Nifty constituents.

Global

Limited direct global linkage; however, pharma/industrial margin surprises can influence broader EM sentiment.

Counterpoint

What could challenge this read

If most prints are broadly in-line, the market may fade pre-positioning and trade more on guidance than on headline earnings.

Key entities

  • event
    Q4 earnings calendar (29 May)

    Multiple Indian listed companies are scheduled to announce Q4 results, creating near-term catalysts.

  • company
    Alkem Laboratories

    Article cites a large pre-session surge and standalone net profit plus a final dividend recommendation.

  • company
    ESAB India

    Analyst first-cut provides Q4 and FY26 consolidated revenue/EBITDA/PAT and margin drivers.

  • company
    Ivalue Infosolutions

    Analyst first-cut provides Q4 revenue/EBITDA/PAT beats vs estimates and cash-flow improvement.

Read at source← All news

Related articles

AUG 13
$ESABMedAI 8/10

ESAB (ESAB) Q2 2026 Earnings Call Transcript

ESAB (ESAB) reported Q2 2026 core sales of $766 million, up 13% year over year, with 2.5% core organic growth. Adjusted EBITDA was $150 million, up 8%, and margin was 19.5%. Full-year guidance: core sales $3.0-$3.1B, adjusted EBITDA $615-$625M, adjusted EPS $5.40-$5.50, including Eddyfi. Middle East sales fell 10%-11% amid conflict.

fool.com6 min
AUG 12
$INFYMed

Aug 12: Markets Extend Losses as Tata Stocks, IT Shares Drag; Nifty Slips Below 24,450 – The Indian Awaaz

Indian benchmarks extended losses. The Nifty 50 fell 35.75 points, or 0.15%, to 24,435.95, and the Sensex dropped 187.90 points, or 0.24%, to 77,966.35. Tata stocks and IT shares weighed after Tata Sons chairman N Chandrasekaran said he will not seek reappointment. TCS fell 3.93% and Infosys 1.23%. India CPI inflation rose to 4.45% in July, from 4.38% in June.

theindianawaaz.com7 min
AUG 10
$ESABMedAI 8/10

ESAB Q2 Deep Dive: Equipment Strength and Eddyfi Integration Drive Strategic Shift

ESAB reported Q2 revenue of $807.6 million, above analysts’ $787.2 million, with adjusted EPS of $1.33 versus $1.37 expected. Adjusted EBITDA was $151.4 million, slightly above estimates. Full-year adjusted EPS guidance of $5.45 and EBITDA guidance of $620 million both missed. Management cited equipment and automation strength and Eddyfi integration, while Middle East revenue fell due to geopolitical disruption and higher logistics costs.

yahoo.com6 min
AUG 9
$ESABMedAI 8/10

ESAB Q2 Earnings Call Highlights

ESAB (NYSE:ESAB) discussed its Q2 earnings call and Eddyfi integration. Management said Eddyfi has high-single-digit growth, ~65% gross margins and ~30% EBITDA margins, with a ~$450 million commercial funnel. ESAB raised FY2026 outlook to core sales of ~$3.0-3.1B, adjusted EPS $5.40-5.50, and adjusted EBITDA $615-625M.

yahoo.com6 min
AUG 6
$ESABMed

ESAB’s (NYSE:ESAB) Q2 CY2026 Sales Beat Estimates

ESAB (NYSE:ESAB) reported Q2 CY2026 revenue of $807.6 million, up 12.9% year over year, exceeding Wall Street estimates by 2.6%. Non-GAAP EPS was $1.33, down from $1.36 a year earlier and 3% below consensus. Operating margin fell to 9.7% from the prior year. Analysts expect full-year EPS to rise from $5.31 to $6.08.

financialcontent.com4 min
AUG 6
$ESABHigh

ESAB Corp (ESAB): Results of Operations and Financial Condition

ESAB Corp (ESAB) filed an SEC Form 8-K — Results of Operations and Financial Condition. ESAB Corporation Announces Second Quarter 2026 Results • Record total sales increased 12.9%, with core organic sales up 2.5% • Core organic growth in both segments • Closed Eddyfi ahead of schedule • Updating 2026 outlook North Bethesda, MD, August 6, 2026 -- ESAB Corporation (“E

SEC EDGAR 8-K6 min